Keros Therapeutics (NASDAQ:KROS) Price Target Raised to $111.00

Keros Therapeutics (NASDAQ:KROS) had its price objective raised by Wells Fargo & Company from $88.00 to $111.00 in a research note released on Wednesday morning,Benzinga reports. Wells Fargo & Company currently has an overweight rating on the stock.

Several other research firms have also issued reports on KROS. Bank of America cut their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a report on Thursday, September 12th. HC Wainwright restated a “buy” rating and set a $100.00 target price on shares of Keros Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Wedbush restated an “outperform” rating and set a $84.00 price target on shares of Keros Therapeutics in a research note on Thursday, November 7th. Finally, Guggenheim restated a “buy” rating and set a $102.00 price objective (up previously from $96.00) on shares of Keros Therapeutics in a report on Wednesday, December 4th. Three research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Keros Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.67.

Keros Therapeutics Price Performance

Shares of KROS stock opened at $18.83 on Wednesday. The stock’s 50-day moving average is $59.11 and its 200 day moving average is $52.63. Keros Therapeutics has a 1-year low of $15.67 and a 1-year high of $73.00. The company has a market cap of $762.75 million, a P/E ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business’s quarterly revenue was up 4750.0% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.33) EPS. On average, analysts anticipate that Keros Therapeutics will post -5.26 EPS for the current year.

Institutional Trading of Keros Therapeutics

Several large investors have recently made changes to their positions in KROS. KBC Group NV raised its holdings in shares of Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock worth $73,000 after purchasing an additional 432 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 26.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock valued at $77,000 after buying an additional 280 shares during the period. Values First Advisors Inc. purchased a new stake in shares of Keros Therapeutics in the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Keros Therapeutics in the second quarter worth about $128,000. Finally, LMR Partners LLP acquired a new stake in Keros Therapeutics during the third quarter worth about $213,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.